Skip to main content
[Preprint]. 2021 Jan 8:2021.01.08.425793. [Version 1] doi: 10.1101/2021.01.08.425793

Figure 7. Extracellular vimentin as a potential target for inhibiting SARS-CoV-2 entry.

Figure 7.

A diagram of proposed mechanism of action. Here, cell surface vimentin (green) acts as a co-receptor that binds to SARS-CoV-2 spike protein. Blocking this interaction via the anti-vimentin antibody Pritumumab reduces cell surface binding of the virus and cellular infection. Schematics generated with Biorender.com.